Robert Mamoun
Chief Executive Officer Ciloa
Seminars
Wednesday 28th October 2026
Industry Leaders Fireside Chat: Driving Access, Therapeutic Advances & Scale to Position Europe as the Next Obesity Innovation Hub
8:45 am
- Discussing the European Obesity Landscape to accelerate innovation
- Explore the most promising innovations beyond first-generation obesity therapeutics to guide future pipelines and strategic investment decisions
- Address the real-world challenges of infrastructure and adoption to expand patient access and commercial reach across Europe
Wednesday 28th October 2026
A Biomimetic Adiponectin–Extracellular Vesicle (APN-EV) Combined with GLP-1: Efficacy in Preclinic
12:15 pm
- Introducing APN-EV, the first stable, functional multimeric adiponectin, to improve insulin sensitivity and drive fat clearance
- Demonstrating synergistic fat loss with microdose APN-EV and GLP-1R agonists to enhance efficacy while preserving muscle mass and address the sarcopenia challenges associated with incretin-based therapies
- Exploring the translational and commercial potential of the EV platform, including manufacturing scalability, cost-of-goods advantages
